{"filing":{"accession_number":"0001193125-26-392527","cik":"0001520262","ticker":"ALKS","company_name":"Alkermes plc.","form":"8-K","filing_date":"2026-09-16","report_date":"2026-09-14","primary_document":"alks-20260914.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1520262/000119312526392527/alks-20260914.htm"},"events":[{"id":33807,"run_id":31109,"accession_number":"0001193125-26-392527","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Alkermes appointed Anne C. Whitaker as an independent director to its Board of Directors, effective immediately, increasing the Board size from 10 to 11 directors. Ms. Whitaker, a seasoned biopharmaceutical executive with extensive commercial, operational, and board experience, will receive standard director compensation including an annual cash retainer, equity grant, and a $600,000 initial new director equity award.","company_name":"Alkermes plc.","ticker":"ALKS","filing_date":"2026-09-16","form":"8-K","submitted_at":null,"items":[{"id":37343,"accession_number":"0001193125-26-392527","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Anne C. Whitaker as a new independent director to Alkermes' Board, effective immediately, with the Board size increasing from 10 to 11 directors. While the disclosure also includes compensatory arrangements (annual cash retainer, equity grant, and a $600,000 initial new director equity award), the principal action disclosed is the appointment itself. The language \"appointed Anne C. Whitaker to the Board, effective immediately\" and the press release headline \"Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors\" make the appointment the salient event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-16T13:14:41.333433+00:00","company_name":"","ticker":null,"filing_date":""},{"id":37344,"accession_number":"0001193125-26-392527","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Anne C. Whitaker as an independent director to Alkermes' Board of Directors, announced via press release on September 16, 2026. The prose explicitly states \"Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors\" and describes her as \"a seasoned biopharmaceutical executive and experienced board director\" with extensive commercial, operational, and board experience. This is a clear executive appointment event material to investors assessing board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-16T13:14:41.333433+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37343,"accession_number":"0001193125-26-392527","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Anne C. Whitaker as a new independent director to Alkermes' Board, effective immediately, with the Board size increasing from 10 to 11 directors. While the disclosure also includes compensatory arrangements (annual cash retainer, equity grant, and a $600,000 initial new director equity award), the principal action disclosed is the appointment itself. The language \"appointed Anne C. Whitaker to the Board, effective immediately\" and the press release headline \"Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors\" make the appointment the salient event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-16T13:14:41.333433+00:00","company_name":"Alkermes plc.","ticker":"ALKS","filing_date":"2026-09-16"},{"id":37344,"accession_number":"0001193125-26-392527","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Anne C. Whitaker as an independent director to Alkermes' Board of Directors, announced via press release on September 16, 2026. The prose explicitly states \"Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors\" and describes her as \"a seasoned biopharmaceutical executive and experienced board director\" with extensive commercial, operational, and board experience. This is a clear executive appointment event material to investors assessing board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-16T13:14:41.333433+00:00","company_name":"Alkermes plc.","ticker":"ALKS","filing_date":"2026-09-16"}]}